What is Trevena?
Trevena, Inc. is a biopharmaceutical firm dedicated to creating and commercializing novel medicines for patients suffering from CNS disorders. Their approved product in the U.S. is OLINVYK® (oliceridine) injection, an intravenous opioid analgesic for severe acute pain where alternative treatments are insufficient. The company's pipeline, built on Nobel Prize-winning research, features four distinct investigational drug candidates: TRV250 for acute migraine treatment, TRV734 for opioid use disorder maintenance, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting associated with COVID-19. The company's current lifecycle stage appears to be in a scaling phase, indicated by the major enterprise-level funding it has received.
How much funding has Trevena raised?
Trevena has raised a total of $110.8M across 4 funding rounds:
Stock Offering
$64.8M
Other Financing Round
$40M
Share Placement
$4M
Debt
$2M
Stock Issuance/Offering (2014): $64.8M, investors not publicly disclosed
Other Financing Round (2022): $40M led by CBC Group
Share Placement (2023): $4M, investors not publicly disclosed
Debt (2024): $2M featuring R Bridge Group
Key Investors in Trevena
R Bridge Group
R Bridge Group LLC is a management consulting firm that likely provides strategic advisory services to support Trevena's growth and operational efficiency.
CBC Group
CBC Group is a significant backer, suggesting a strategic interest in Trevena's biopharmaceutical advancements and market potential.
What's next for Trevena?
With the recent injection of $2M through a major strategic investment, Trevena is poised to accelerate the development and commercialization of its innovative pipeline. The company's focus on differentiated investigational drug candidates for significant unmet medical needs, such as migraine, opioid use disorder, and neuropathic pain, positions it for potential breakthroughs. Future strategic financing rounds or partnerships will likely be crucial for advancing these candidates through clinical trials and towards market approval, further solidifying Trevena's role in the biopharmaceutical landscape.
See full Trevena company page
